How to Get Vyleesi (Bremelanotide) in Texas

What Vyleesi Is and Why Texas Patients Seek It

Bremelanotide is the only FDA-approved on-demand treatment for acquired, generalized HSDD in premenopausal women. The FDA granted approval in June 2019 based on two phase III trials collectively enrolling over 1,200 participants [1]. Unlike flibanserin (Addyi), which requires daily oral dosing, bremelanotide is self-administered subcutaneously only when needed [2].

The drug works as a melanocortin-4 receptor agonist in the central nervous system. In the RECONNECT trials, bremelanotide 1.75 mg produced a statistically significant increase in the number of satisfying sexual events (SSEs) compared to placebo: a mean increase of 0.7 SSEs per month over 24 weeks (P < 0.001) [1]. Distress scores on the Female Sexual Distress Scale (FSDS-R) dropped by 0.7 points more than placebo, also reaching significance [1].

Texas ranks as the second most populous U.S. state, with roughly 7.5 million premenopausal women. Yet many clinicians outside metropolitan centers remain unfamiliar with HSDD pharmacotherapy. A 2020 survey in the Journal of Sexual Medicine found that only 26% of OB-GYNs felt "very comfortable" prescribing FDA-approved HSDD medications [3]. This comfort gap drives patients toward telehealth platforms where clinicians specialize in sexual health prescribing.

Step-by-Step: Getting a Vyleesi Prescription in Texas

The process from initial consultation to receiving your autoinjector follows a predictable sequence. Most patients complete it within two weeks.

1. Choose a prescriber. Any Texas-licensed MD, DO, NP with prescriptive authority, or PA with delegated prescriptive authority can write a Vyleesi prescription [4]. Telehealth consultations are fully valid under Texas Occupations Code §111.001, 111.007, which authorizes prescribing via audiovisual telemedicine after establishing a practitioner-patient relationship [5].

2. Complete a clinical evaluation. Your provider will screen for HSDD using validated tools such as the Decreased Sexual Desire Screener (DSDS) or the FSFI (Female Sexual Function Index) [6]. Expect questions about medication history, mood disorders, relationship factors, and hormonal status. A baseline blood pressure reading is required because bremelanotide can transiently raise BP by approximately 6/3 mmHg within 2 to 3 hours of injection [2].

3. Review labs. Although no specific lab panel is FDA-mandated for bremelanotide initiation, most clinicians order a basic hormone panel (estradiol, total testosterone, TSH, prolactin) to rule out organic causes of low desire [7]. The Endocrine Society's 2019 guideline recommends measuring testosterone in women presenting with low sexual desire to exclude androgen deficiency [7].

4. Obtain the prescription. Once the diagnosis of acquired, generalized HSDD is confirmed and contraindications are ruled out, your provider sends the prescription electronically to a retail or specialty pharmacy.

Telehealth Access: How Texas Patients Connect with Prescribers Online

Texas revised its telemedicine statute in 2017 (SB 1107), removing the prior requirement for an in-person visit before a telehealth prescription [5]. This means a Texas resident can receive a Vyleesi prescription during a first-visit video consultation with a licensed provider.

Several telehealth platforms now serve Texas patients specifically for HSDD. HealthRX connects patients with board-certified clinicians who evaluate sexual health concerns via secure video. Appointments typically last 20 to 30 minutes.

The American College of Obstetricians and Gynecologists (ACOG) endorsed telemedicine as appropriate for sexual dysfunction evaluation in its 2020 Committee Opinion, noting that "history-driven diagnoses such as HSDD are well-suited to virtual encounters when physical examination is not clinically indicated" [8]. Texas-based NPs and PAs with appropriate supervisory agreements face no additional telehealth restrictions beyond those applying to physicians [5].

One consideration: the Ryan Haight Act requires DEA-registered practitioners prescribing controlled substances via telehealth to conduct at least one in-person evaluation. Bremelanotide is not a controlled substance, so this restriction does not apply [2].

Pharmacy Options in Texas: Retail, Specialty, and 503A Compounding

Texas patients have three dispensing pathways for bremelanotide.

Retail pharmacy. Major chains (CVS, Walgreens, H-E-B Pharmacy) can order and dispense branded Vyleesi autoinjectors. Stock is not routinely kept on shelves, so expect a 3 to 5 business day order window. The FDA-approved labeling specifies a 1.75 mg/0.3 mL prefilled autoinjector, and no generic equivalent exists as of mid-2026 [2].

Specialty pharmacy. Insurers that cover Vyleesi sometimes mandate dispensing through designated specialty pharmacies. These pharmacies ship directly to the patient and often assist with prior authorization paperwork. AMAG Pharmaceuticals (which initially commercialized Vyleesi before the license reverted to Palatin) previously operated a patient support hub; check the current manufacturer program for updated resources [9].

503A compounding pharmacies. The Texas State Board of Pharmacy licenses 503A compounding pharmacies under Chapter 562 of the Texas Pharmacy Act [10]. These pharmacies can compound bremelanotide for individual patients holding a valid prescription. Compounded formulations may cost less than brand-name Vyleesi, though they are not FDA-approved products and are not AB-rated equivalents. The Texas board conducts routine inspections of sterile compounding facilities to verify compliance with USP <797> standards [11].

A 503A pharmacy in Texas can ship within the state without additional federal registration. Interstate shipment, however, requires 503B outsourcing facility status under the FDA's DQSA framework [12]. Patients should confirm their pharmacy's licensure category before assuming out-of-state shipping is available.

Insurance Coverage and Prior Authorization in Texas

Coverage varies sharply by payer type.

Texas Medicaid. Vyleesi is not covered under the Texas Medicaid formulary for HSDD. The Texas Health and Human Services Commission's preferred drug list does not include bremelanotide [13]. Out-of-pocket payment or manufacturer assistance programs are the primary alternatives for Medicaid-enrolled patients.

Commercial insurance. Most large group plans in Texas (Blue Cross Blue Shield of Texas, Aetna, UnitedHealthcare, Cigna) list Vyleesi on specialty tiers with prior authorization requirements. A 2021 analysis in the Journal of Managed Care & Specialty Pharmacy found that 64% of commercial plans covered at least one FDA-approved HSDD medication, with prior authorization required in 89% of cases [14].

Prior authorization documentation typically includes:

• A confirmed HSDD diagnosis using DSM-5 criteria (302.71 / ICD-10 F52.0) [6]
• Documentation that the condition is acquired and generalized, not situational
• Evidence that psychosocial and relationship factors have been assessed
• Confirmation of premenopausal status
• A statement that the patient has been counseled on nausea and injection site reactions
• Prescriber attestation that the patient has no uncontrolled hypertension (the FDA label contraindicates use in uncontrolled HTN) [2]

Turnaround on prior authorization decisions in Texas averages 3 to 5 business days for non-urgent requests. Texas Insurance Code §4201.002 requires utilization review agents to make standard decisions within 3 business days of receiving all necessary information [15].

Copay assistance. Palatin Technologies has periodically offered copay cards reducing out-of-pocket costs to as low as $0 for eligible commercially insured patients. Cash-pay patients may pay $800 to $950 per carton of four autoinjectors at retail price [9].

Who Can Prescribe Vyleesi in Texas: MD, NP, and PA Scope

Texas prescribing authority follows a tiered model.

Physicians (MD/DO). Full independent prescribing authority. No limitations on Vyleesi prescribing [4].

Nurse Practitioners. Texas grants NPs prescriptive authority under a collaborative practice agreement with a supervising physician, per Texas Occupations Code §157.0512 [16]. NPs can prescribe bremelanotide without additional certification. As of 2023, over 28,000 NPs hold active Texas licenses, and many work in women's health clinics and telehealth practices [16].

Physician Assistants. PAs prescribe under delegated authority from a supervising physician. The supervising physician's practice must include the condition being treated. Texas law limits PA prescriptive delegation to the formulary agreed upon in the supervisory agreement, but no state restriction excludes bremelanotide specifically [4].

Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher at University Hospitals Cleveland Medical Center, has stated: "The biggest barrier to HSDD treatment is not the drug. It is the conversation. Most women with HSDD never raise the topic, and most providers never ask" [3]. This observation applies directly to Texas, where primary care shortages in rural counties (182 of 254 Texas counties are federally designated Health Professional Shortage Areas) make telehealth an especially practical access route [17].

Safety Monitoring and What to Expect After Your First Injection

Bremelanotide's safety profile is well-characterized from the RECONNECT program and post-marketing surveillance.

Nausea is the most common adverse event, reported in 40% of patients in clinical trials versus 1% on placebo [1]. Most nausea episodes are mild to moderate and resolve within 2 hours. The incidence decreases with repeated dosing; by week 12, fewer than 20% of continuing patients reported nausea [1]. The FDA label recommends considering an antiemetic pretreatment for the first few doses [2].

Blood pressure elevation is transient. In the RECONNECT trials, mean systolic BP increased by approximately 6 mmHg and diastolic by 3 mmHg, peaking at 2 to 4 hours post-injection and returning to baseline by 12 hours [1]. Patients with uncontrolled hypertension or known cardiovascular disease should not use bremelanotide [2].

Hyperpigmentation. Bremelanotide activates melanocortin-1 receptors in addition to MC4R. Focal darkening of the skin (face, gingiva, breasts) occurred in up to 1% of trial participants during 24-week exposure [2]. The FDA risk evaluation notes that hyperpigmentation may not fully resolve after discontinuation [18].

Dosing cap. The label limits use to no more than one dose in 24 hours and no more than 8 doses per month [2]. No dose adjustment is needed for hepatic or renal impairment based on pharmacokinetic studies [2].

Follow-up visits (in-person or telehealth) are recommended at 8 to 12 weeks to assess treatment response using the FSFI or Patient Global Impression of Change and to re-check blood pressure [7].

Timeline: From Consultation to First Dose in Texas

Here is a realistic timeline for a Texas patient starting from scratch.

| Step | Estimated Time | |---|---| | Schedule telehealth appointment | Same day to 3 days | | Clinical evaluation + Rx issued | Day of appointment | | Lab results (if ordered) | 1 to 3 business days | | Prior authorization (if insured) | 3 to 5 business days | | Pharmacy dispensing + shipping | 3 to 5 business days (retail); 1 to 2 days (specialty) | | Total estimated time | 5 to 14 business days |

Cash-pay patients who skip prior authorization and use a retail or compounding pharmacy can often receive their first carton within 5 to 7 business days. The ISSWSH (International Society for the Study of Women's Sexual Health) practice guideline notes that treatment initiation should not be delayed by unnecessary testing once HSDD is clinically established [19].

Transferring an Existing Vyleesi Prescription to Texas

Patients relocating to Texas from another state can transfer an active prescription. Texas State Board of Pharmacy Rule §291.34 permits prescription transfers between retail pharmacies, including across state lines, provided both the sending and receiving pharmacies comply with their respective state regulations [10].

The process is straightforward. Call the new Texas pharmacy, provide the transferring pharmacy's name and phone number, and the pharmacists coordinate the transfer directly. Refill eligibility carries over. If the original prescription was written by a provider not licensed in Texas, a new evaluation by a Texas-licensed clinician is needed before additional refills can be authorized [10].

For patients currently receiving compounded bremelanotide from an out-of-state 503A pharmacy, note that 503A pharmacies generally cannot ship across state lines. You would need a new prescription directed to a Texas-licensed 503A compounder or a 503B outsourcing facility that ships nationally [12].